Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 10, 2018, 10:12:11 am
-
Twelve weeks of Gilead Sciences’ Epclusa (sofosbuvir/velpatasvir) boasts a high success rate in treating those with genotype 3 of hepatitis C virus (HCV), even when people have viral mutations associated with drug resistance.
Publishing their findings in Alimentary Pharmacology & Therapeutics, researchers conducted a multicenter cohort study of 293 people with genotype 3 of HCV who received medical care at 10 treatment centers across Germany. The participants were enrolled in the study between July 2016 and August 2017.
For more...
https://www.hepmag.com/article/epclusa-highly-effective-treating-genotype-3-hepatitis-c